Attenuation of methamphetamine-induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment

Chinese Journal of Physiology

Volumn 50, Issue 2, 2007, Pages 51-56

  Lin, Yin Chiu ^a   Kuo, Yu Min ^a   Liao, Pao Chi ^a   Cherng, Chianfang G ^b   Su, Su Wen ^a   Yu, Lung ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b DEPARTMENT OF ELECTRONIC ENGINEERING   (Taiwan)

Author keywords

Dopamine; Methamphetamine; Neurotoxicity; Striatum

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; LIPOPOLYSACCHARIDE; METHAMPHETAMINE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; HYPERTHERMIA; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; ANIMAL; BASAL GANGLION; C57BL MOUSE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; FEVER; IMMUNOLOGY; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY; PHYSIOLOGY;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BASAL GANGLIA; BODY TEMPERATURE; DOPAMINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEVER; LIPOPOLYSACCHARIDES; MALE; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; NEURONS; NEUROPROTECTIVE AGENTS; RECEPTORS, DOPAMINE;

EID: 34547111801     PISSN: 03044920     EISSN: 26660059     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Arai, H., Furuya, T., Yasuda, T., Miura, M., Mizuno, Y. and Mochizuki, H. Neurotoxic effects of LPS on nigrostriatal dopaminergic neurons are mediated by microglial activation, interleukin-1B, and expression of caspase-11 in mice. J. Biol. Chem. 279: 51647-51653, 2004.
2. Broening, H.W., Morford, L.L. and Vorhees, C.V. Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions. Synapse 56: 84-93, 2005.
3. Cadet, J.L., Ali, S. and Epstein, C. Involvement of oxygen-based radicals in methamphetamine-induced neurotoxicity: evidence from the use of CuZn-SOD transgenic mice. Ann. N. Y. Acad. Sci. 738: 388-391, 1994.
4. Davis, A.E.M.; Campbell, S.J., Wilainam, P. and Anthony, D.C. Post-conditioning with lipopolysaccharide reduces the inflammatory infiltrate to the injured brain and spinal cord: a potential neuroprotective treatment. Eur. J. Neurosci. 22: 2441-2450, 2005.
5. Escubedo, E., Chipana, C., Perez-Sanchez, M., Camarasa, J. and Pubill, D. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: involvement of α7 nicotinic receptors. J. Pharmacol. Exp. Ther. 315: 658-667, 2005.
6. Flora, G., Lee, Y.W., Nath, A., Maragos, W., Hennig, B. and Toborek, M. Methamphetamine-induced TNF-alpha gene expression and activation of AP-1 in discrete regions of mouse brain: potential role of reactive oxygen intermediates and lipid peroxidation. Neuromolecular Med. 2: 71-85, 2002.
7. Flora, G., Lee, Y.W., Nath, A., Hennig, B., Maragos, W. and Toborek, M. Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain. Exp. Neurol. 179: 60-70, 2003.
8. Fukumura, M., Cappon, G.D., Pu, C., Broening, H.W. and Vorhees, C.V. A single dose model of methamphetamine-induced neurotoxicity in rats: effects on neostriatal monoamines and glial fibrillary acidic protein. Brain Res. 806: 1-7, 1998.
9. Fumagalli, F., Gainetdivov, R.R., Wang, Y.M., Valenzano, K.J., Miller, G.W. and Caron, M.G. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knockout mice. J. Neurosci. 19: 2424-2431, 1999.
10. Gao, H.M., Liu, B., Zhang, W. and Hong, J.S. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. FASEB J. 17: 1957-1959, 2003.
11. Gayle, D.A., Ling, Z., Tong, C., Landers, T., Lipton, J.W. and Carvey, P.M. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1 beta, and nitric oxide. Brain Res. Dev. Brain Res. 133: 27-35, 2002.
12. Hirsch, E.C., Hunot, S. and Hartmann, A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat. Disord. Suppl. 1: S9-S15, 2005.
13. In, S-W., Son, E-W., Rhee, D-K. and Pyo, S. Modulation of murine macrophage function by methamphetamine. J. Toxicol. Envir. Health part A 67: 1923-1937, 2004.
14. Kita, T., Saraya, T., Konishi, N., Matsunari, Y., Shimada, K., Nakamura, M., O'Hara, K., Wagner, G.C. and Nakashima, T. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine pretreatment attenuates methamphetamine-induced dopamine toxicity. Pharmacol. Toxicol. 92: 71-80, 2003.
15. Kiyatkin, E.A. Brain hyperthermia as physiological and pathological phenomena. Brain Res. Brain Res. Rev. 50: 27-56, 2005.
16. Kozak, W., Conn, C.A. and Kluger, M.J. Lipopolysaccharide induces fever and depresses locomotor activity in unrestrained mice. Am. J. Physiol. 266: R125-135, 1994.
17. Kuo, Y.M., Chen, H.H., Shieh, C.C., Chuang, K.P., Cherng, C.G. and Yu, L. 4-Hydroxytamoxifen attenuates methamphetamine-induced nigrostriatal dopaminergic toxicity in intact and gonadectomized mice. J. Neurochem. 87: 1436-1443, 2003.
18. Liao, P-C., Kuo, Y-M., Hsu, H-C., Cherng, C.G. and Yu, L. Local proteins associated with methamphetamine-induced nigrostriatal dopaminergic neurotoxicity. J. Neurochem. 95: 160-168, 2005.
19. Ling, Z.D., Chang, Q., Lipton, J.W., Tong, C.W., Landers, T.M. and Carvey, P.M. Combined toxicity of prenatal bacterial endotoxin exposure and posmatal 6-hydroxydopamine in the adult rat midbrain. Neuroscience 124: 619-628, 2004.
20. Nawashiro, H., Tasaki, K., Ruetzler, C.A. and Hallenbeck, J. M. TNF-alpha pretreatment induces protective effects against focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 17: 483-490, 1997.
21. O'Callaghan, J.P. and Miller, D.B. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharm. Exp. Ther. 270: 741-751, 1994.
22. Sanchez-Alavez, M., Gombart, L.M., Huitron-Resendiz, S., Carr, J.R., Wills, D.N., Berg, G., Campbell, I.L., Gauvin, D.V., Henriksen, S.J. and Criado, J.R. Physiological and behavioral effects of methamphetamine in a mouse model of endotoxemia: a preliminary study. Pharmacol. Biochem. Behav. 77: 365-370, 2004.
23. Tasaki, K., Ruetzler, C.A., Ohtsuki, T., Martin, D., Nawashiro, H. and Hallenbeck, J. M. Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneous hypertensive rats. Brain Res. 748: 267-270, 1997.
24. Thomas, D.M., Dowgiert, J., Geddes, T.J., Francescutti-Verbeem, D., Lin, X. and Kuhn, D.M. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci. Lett. 367: 349-354, 2004.
25. Thomas, D.M. and Kuhn, D.M. MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. Brain Res. 1050: 190-198, 2005.
26. Wagner, G.C., Ricaurte, G.A., Seiden, L.S., Schuster, C.R., Miller, J.M. and Westly, J. Long-lasting depletion of striatal DA and loss of DA uptake sites following the repeated administration of methamphetamine. Brain Res. 171:151-160, 1980.
27. Xu, W., Zhu, J.P.Q. and Angulo, J.A. Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors. Synapse 58: 110-121, 2005.
28. Yamamoto, B.K. and Zhu, W. The effects of methamphetamine on the production of free radicals and oxidative stress. J. Pharm. Exp. Ther. 287: 107-114, 1998.
29. Yu, L. and Liao, P-C. Estrogen and progesterone distinctively modulate methamphetamine-induced dopamine and serotonin depletions in C57BL/6J mice. J. Neural Trasm. 107: 1139-1147, 2000.